23andMe launches new genetic report on forms of cancer

23andMe Holding released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as polygenic risk scores, developed by 23andMe through its proprietary research database. These PRS reports calculate the likelihood of an individual developing one of these cancers, based on thousands of genetic variants associated with the disease. “Using these reports to understand your likelihood to develop common cancers is an important step toward further integrating genetics into healthcare,” said Noura Abul-Husn, Vice President of Genomic Health at 23andMe. “Today, there is increasing evidence and support for the use of PRS in personalized disease prevention, and certain medical specialties – including oncology – have already begun to adopt this to inform clinical decision-making. These new reports will help customers better understand their overall likelihood for developing these diseases, and enable them to work with their healthcare providers to implement prevention plans.”